ANX-005 is under clinical development by Annexon and currently in Phase III for Guillain-Barre Syndrome. According to GlobalData, Phase III drugs for Guillain-Barre Syndrome does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ANX-005 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ANX-005 overview
<p>ANX-005 is under development for the treatment and acute antibody-mediated autoimmune disease such as Guillain-Barre syndrome, amyotrophic lateral sclerosis, warm autoimmune hemolytic anemia, Huntington disease. It is administered as intravenous infusion. The drug candidate is a humanized monoclonal antibody that inhibits early components of the classical complement cascade. It is based on composite human antibody technology.</p> <p>The drug candidate was also under development for the treatment of Alzheimer's disease and multifocal motor neuropathy (MMN).</p> <p></p>
Annexon overview
Annexon is a biopharmaceutical company that primarily focuses on the development of therapies for autoimmune, neurodegenerative, and ophthalmic diseases. The company’s mainly focuses on inhibiting C1q, the initiating molecule of the classical complement pathway, to prevent inflammation and tissue damage. Annexon‘s products are intended for use in the healthcare industry, specifically for the treatment of serious autoimmune, neurodegenerative, and ophthalmic diseases. The company operates primarily in the US. Annexon is headquartered in South San Francisco, California, the US.
For a complete picture of ANX-005’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
